These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18957720)

  • 1. K-RAS and P53 mutations in association with COX-2 and hTERT expression and clinico-pathological status of NSCLC patients.
    Strazisar M; Rott T; Glavac D
    Dis Markers; 2008; 25(2):97-106. PubMed ID: 18957720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of p53 and K-ras in lung carcinomas of coal miners.
    Sarkar FH; Li Y; Vallyathan V
    Int J Mol Med; 2001 Oct; 8(4):453-9. PubMed ID: 11562787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).
    Strazisar M; Mlakar V; Glavac D
    Cell Mol Biol Lett; 2009; 14(3):442-56. PubMed ID: 19238334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
    Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
    Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic value of hTERT mRNA expression in patients with non-small-cell lung cancer.
    Zalewska-Ziob M; Dobija-Kubica K; Biernacki K; Adamek B; Kasperczyk J; Bruliński K; Ostrowska Z
    Acta Biochim Pol; 2017; 64(4):641-646. PubMed ID: 29141053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
    Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
    Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of K-ras and p53 mutations in bronchoscopically obtained malignant and non-malignant tissue from patients with non-small cell lung cancer.
    Lang SM; Stratakis DF; Freudling A; Ebelt K; Oduncu F; Hautmann H; Huber RM
    Eur J Med Res; 2000 Aug; 5(8):341-6. PubMed ID: 10958767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-ras gene mutations in non-small cell lung cancer in Japanese.
    Noda N; Matsuzoe D; Konno T; Kawahara K; Yamashita Y; Shirakusa T
    Oncol Rep; 2001; 8(4):889-92. PubMed ID: 11410804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.
    Konishi T; Huang CL; Adachi M; Taki T; Inufusa H; Kodama K; Kohno N; Miyake M
    Int J Oncol; 2000 Mar; 16(3):501-11. PubMed ID: 10675482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
    Grossi F; Loprevite M; Chiaramondia M; Ceppa P; Pera C; Ratto GB; Serrano J; Ferrara GB; Costa R; Boni L; Ardizzoni A
    Eur J Cancer; 2003 Jun; 39(9):1242-50. PubMed ID: 12763212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing.
    Chong IW; Chang MY; Sheu CC; Wang CY; Hwang JJ; Huang MS; Lin SR
    Oncol Rep; 2007 Jul; 18(1):17-24. PubMed ID: 17549340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.
    Fukuyama Y; Mitsudomi T; Sugio K; Ishida T; Akazawa K; Sugimachi K
    Br J Cancer; 1997; 75(8):1125-30. PubMed ID: 9099959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.